What one share of Phio Pharmaceuticals holds
Phio Pharmaceuticals Corp. (“Phio,” “we,” “our” or the “Company”) is a clinical stage biopharmaceutical company whose proprietary INTASYL® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells.
Phio Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.36 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.29 |
| Cash and investments | $1.12 |
| Book value | $1.08 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.00 | −$207.04 | $0.45 | −$207.67 | — | $243.18 |
| 2021 | — | −$111.84 | $0.43 | −$100.24 | — | $175.00 |
| 2022 | — | −$90.91 | $0.96 | −$97.00 | — | $85.64 |
| 2023 | — | −$46.76 | $0.02 | −$46.45 | — | $18.57 |
| 2024 | — | −$9.08 | $0.00 | −$9.03 | — | — |
| 2025 | — | −$1.45 | $0.00 | −$1.34 | — | $1.73 |
Common questions about Phio Pharmaceuticals
How much does one share of Phio Pharmaceuticals earn?
Over the last 12 months, Phio Pharmaceuticals lost $1.36 for each share.
Does Phio Pharmaceuticals pay a dividend?
Phio Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Phio Pharmaceuticals’s book value per share?
Phio Pharmaceuticals’s book value is $1.08 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Phio Pharmaceuticals have?
Each share of Phio Pharmaceuticals has $1.12 of cash and investments, as of June 30, 2026.
What is Phio Pharmaceuticals’s free cash flow per share?
−$1.29 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Phio Pharmaceuticals bought back shares?
Phio Pharmaceuticals’s share count rose about 13988% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.